Abstracts tagged "treatment"

Abstract Number: 1439 • 2016 ACR/ARHP Annual Meeting
The EP4 Receptor Antagonist CR6086 Is More Effective Than Classical NSAID and DMARD Treatment in a Murine Model of Arthritis and in Human RA Synovial Explants
Marije I. Koenders¹, Monique M. Helsen¹, Birgitte Walgreen¹, Wim B. van den Berg¹, Gianfranco Caselli², Ornella Letari² and Peter M. van der Kraan¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Rottapharm Biotech, Monza, Italy
Background/Purpose: CR6086 is a novel small molecule acting as a potent and selective antagonist of the prostaglandin E2 (PGE2) receptor EP4 subtype (EP4 receptor). Recent…
Abstract Number: 3224 • 2016 ACR/ARHP Annual Meeting
Efficacy of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Based upon Prior Use of Non-Anti-TNF Biologics in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Global Phase 3 Study
Yoshiya Tanaka¹, Daniel Aletaha², Clifton Bingham III³, Prasheen Agarwal⁴, Regina Kurrasch⁵ and Sharon Popik⁴, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GlaxoSmithKline, King of Prussia, PA
Background/Purpose: A global, phase 3 study (SIRROUND-T) evaluating the efficacy and safety of sirukumab, a selective, high-affinity human monoclonal antibody to IL-6, has recently been…
Abstract Number: 1615 • 2016 ACR/ARHP Annual Meeting
Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Significantly Improves Physical Function and Reduces Morning Stiffness in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Global, Randomized, Placebo-Controlled, Phase 3 Trial
Yoshiya Tanaka¹, Clifton Bingham III², Daniel Aletaha³, Prasheen Agarwal⁴, Sharon Popik⁴, Regina Kurrasch⁵, Steve Peterson⁴, Rita Ganguly⁵, Chenglong Han⁴ and Kelly McQuarrie⁴, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GlaxoSmithKline, Collegeville, PA
Background/Purpose: Improvement in physical function and morning stiffness are key goals of rheumatoid arthritis (RA) treatment. Sirukumab, a selective human anti–IL6 monoclonal antibody, has recently…
Abstract Number: 1625 • 2016 ACR/ARHP Annual Meeting
Analysis of a Phase 3 Study Evaluating the Efficacy of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, Across Subgroups in Patients with Active Rheumatoid Arthritis Despite Treatment with Disease-Modifying Anti-Rheumatic Drugs
Carter Thorne¹, George Karpouzas², Tsutomu Takeuchi³, Shihong Sheng⁴, Weichun Xu⁴, Ravi Rao⁵, Kaiyin Fei⁴ and Benjamin Hsu⁴, ¹University of Toronto and Southlake Regional Health Centre, Newmarket, ON, Canada, ²Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ³Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, and is under development for rheumatoid arthritis (RA)…
Abstract Number: 1641 • 2016 ACR/ARHP Annual Meeting
Survival of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Zulema Rosales Rosado^1,2, Leticia León¹, Dalifer Freites Núñez², Judit Font Urgelles², Cynthia Milagros León Cárdenas², Cristina Vadillo Font², Luis Rodriguez Rodriguez¹, Juan A Jover Jover² and Lydia Abásolo Alcázar¹, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: After more than twenty years using Disease Modifying Drugs (DMARDs) is widely known their efficacy in the treatment of Rheumatoid Arthritis (RA) but it…
Abstract Number: 2233 • 2016 ACR/ARHP Annual Meeting
Predictors of Adherence and Costs in First and Second Years after Biologic Initiation in Patients with Rheumatoid Arthritis (RA)
Bradley S. Stolshek¹, Sally W. Wade², Ajita De³, Ron L. Wade³ and Jason Yeaw³, ¹Amgen, Thousand Oaks, CA, ²Wade Outcomes Research and Consulting, Salt Lake City, UT, ³IMS Health, Plymouth Meeting, PA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease requiring continuous therapy to reach low disease activity targets and to delay its long-term health effects.…
Abstract Number: 2481 • 2016 ACR/ARHP Annual Meeting
Infliximab Low Levels at Early Stages Predict the Loss of Drug Levels and the Clinical Response at One Year of Treatment in Patients with Rheumatoid Arthritis
Teresa Jurado¹, Chamaida Plasencia-Rodriguez², Ana Martínez³, Victoria Navarro-Compán⁴, Eva Olariaga-Merida⁵, Diana Peiteado⁶, Alejandro Villalba⁶, Gema Bonilla⁶, Cristina Diego⁷, Alejandro Balsa² and Dora Pascual-Salcedo⁸, ¹Immunology, University Hospital La Paz, Madrid, Spain, ²Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain, ³Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, ⁴Rheumatology, University Hospital La Paz, Madrid, Spain, ⁵Immunlogy, University Hospital La Paz, Madrid, Spain, ⁶Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ⁷Immunology, Hospital La Paz. IdiPaz, Madrid, Spain, ⁸Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain
Background/Purpose: The anti-TNF monoclonal antibody Infliximab (Ifx), has proven effective in treating rheumatoid arthritis (RA), although in 40% of cases may fail, mainly due to…
Abstract Number: 2488 • 2016 ACR/ARHP Annual Meeting
A Randomised Controlled Trial Evaluating the Effect of Adalimumab upon Biomarkers of Cardiovascular Risk in ACPA-Positive Rheumatoid Arthritis
Stephen Oakley^1,2, Gabor Major^3,4, David Mathers⁵, John van der Kallen⁶, Mark Collins⁷, Marc Toh⁸, Siva Ratnarajah⁸, Theo de Malmanche⁹ and Niloofar Esmaili¹⁰, ¹Rheumatology, Hunter New England Local Health District, New Lambton, Australia, ²School of Medicine & Public Health, University of Newcastle, Newcastle, Australia, ³Medicine, University of Newcastle, Newcastle, Australia, ⁴Rheumatology, Bone and Joint Institute, John Hunter Hospital NSW Australia, Newcastle, Australia, ⁵Rheumatology, Hunter New England Local Health District, Georgetown, Australia, ⁶Georgetown Arthritis, Georgetown, Australia, ⁷Private Practice, Broadmeadow, Australia, ⁸Rheumatology, Private Practice, Newcastle, Australia, ⁹Immunology, Hunter New England Local Health District, New Lambton, Australia, ¹⁰Rheumatology, Hunter New England Health, Newcastle, Australia
Background/Purpose: Rheumatoid Arthritis (RA) is associated with increased cardiovascular (CV) risk. The mechanisms of CV disease in RA remain poorly understood. Observational data suggest that…
Abstract Number: 2535 • 2016 ACR/ARHP Annual Meeting
Effect of Methotrexate in the Presence of Drug and the Appearance of Antibodies Against Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Chamaida Plasencia-Rodriguez¹, Ana Martínez², Alejandro Villalba³, Teresa Jurado⁴, Eva Olariaga-Merida⁵, Araceli Mezcua⁶, Diana Peiteado³, Gema Bonilla³, Laura Nuño³, Alejandro Balsa¹ and Dora Pascual-Salcedo², ¹Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain, ²Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ³Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ⁴Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, ⁵Immunology, University Hospital La Paz, Madrid, Spain, ⁶Immunology Unit, La Paz University Hospital, Madrid, Spain
Background/Purpose: Several factors influence pharmacokinetics of TNFinhibitors (TNFi). One relevant factor is the formation of anti drug- antibodies (ADA) associated with low drug levels and…
Abstract Number: 2581 • 2016 ACR/ARHP Annual Meeting
Tripterygium Wilfordii Hook F Applied Topically in Patients with Active Rheumatoid Arthritis
Juan Jiao¹, Hai-bo Yin², Xiao-po Tang², Xun Gong² and Quan Jiang¹, ¹Rheumatology Department, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, ²Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
Background/Purpose: Tripterygium wilfordii Hook F (TwHF), a traditional Chinese herb, is widely used in China for treating Rheumatoid Arthritis (RA), but limited only for eldly…
Abstract Number: 969 • 2015 ACR/ARHP Annual Meeting
Namilumab, an Anti-Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Monoclonal Antibody: Results of the First Study in Patients with Mild-to-Moderate Rheumatoid Arthritis (RA)
T. W. J. Huizinga¹, Anastas Batalov², Rumen Stoilov³, Eric Lloyd⁴, Thomas Wagner⁵, Didier Saurigny⁶, Bernard Souberbielle⁶ and Ehsanollah Esfandiari⁶, ¹Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²UMHAT Kaspela, Plovdiv, Bulgaria, ³University Hospital (MHAT) St Ivan Rilski, Sofia, Bulgaria, ⁴Takeda Pharmaceuticals, Deerfield, IL, ⁵Takeda Pharmaceuticals, Zurich, Switzerland, ⁶Takeda Pharmaceuticals, London, United Kingdom
Background/Purpose: GM-CSF mediates a range of immunological processes, such as stimulating the production of inflammatory mediators and differentiation of proinflammatory T-helper 17 cells, and may…
Abstract Number: 3194 • 2015 ACR/ARHP Annual Meeting
Oral to Subcutaneous Methotrexate Dose-Conversion Strategies in the Treatment of Rheumatoid Arthritis
Michael Schiff¹ and Peter Sadowski², ¹Division of Rheumatology, University of Colorado, Denver, CO, ²Antares Pharma Inc., Minneapolis, MN
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) therapy1 but absorption saturation limitations compromise oral MTX bioavailability (BA). Subcutaneous (SC) MTX has a…
Abstract Number: 970 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Sarilumab in Combination with Csdmards in Patients with Active Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant of Anti–TNF-Î± Therapy: Results from a Phase 3 Study
Roy Fleischmann¹, Geraldo Castelar-Pinheiro², Jan Brzezicki³, Pawel Hrycaj⁴, Yong Lin⁵, Janet van Adelsberg⁶, Neil Graham⁷, Hubert van Hoogstraten⁵, Deborah Bauer⁵ and Gerd Burmester⁸, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Discipline of Rheumatology, Rio de Janeiro State University, Rio de Janeiro, Brazil, ³Centrum Kliniczno-Badawcze, Elblag, Poland, ⁴Poznan University of Medical Sciences, Poznan, Poland, ⁵Sanofi, Bridgewater, NJ, ⁶Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, ⁷Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁸Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The investigational agent sarilumab is a human mAb directed against the IL-6 receptor. The phase 3 MOBILITY study (NCT01061736) evaluated the efficacy and safety…
Abstract Number: 3243 • 2015 ACR/ARHP Annual Meeting
A Randomized Controlled Trial for a Physical Activity Intervention for RA Fatigue
Patricia P. Katz¹, Mary Margaretten², Steven Gregorich¹, Sandi Kaplan³, Stephanie Rush⁴ and Laura Trupin¹, ¹Medicine, University of California San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Arthritis Research Group, University of California, San Francisco, CA, ⁴University of California, San Francisco, San Francisco, CA
Background/Purpose: Fatigue is a major problem for people with RA. Physical inactivity is an indirect risk factor for fatigue1. We tested the effect of a…
Abstract Number: 1280 • 2015 ACR/ARHP Annual Meeting
Comparison of Health Service Utilization Costs Between Aboriginal and Non-Aboriginal Patients with Rheumatoid Arthritis Requiring Biologic Therapy
Cheryl Barnabe¹, Yufei Zheng², Arto Ohinmaa², Brenda Hemmelgarn³, Gilaad Kaplan⁴, Liam Martin⁵ and Walter Maksymowych⁶, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Institute of Health Economics, Edmonton, AB, Canada, ³Division of Nephrology, University of Calgary, Calgary, AB, Canada, ⁴Division of Gastroenterology, University of Calgary, Calgary, AB, Canada, ⁵Medicine, University of Calgary, Calgary, AB, Canada, ⁶Medicine, Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Logistical issues and poor cultural environments in tertiary care create barriers to specialized care for Aboriginal patients with rheumatoid arthritis (RA). Aboriginal patients are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].